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Abstract 
Introduction: The post-translational oxidation of methionine to methionine sulfoxide is a 
reversible process, enabling repair of oxidative damage to proteins and the use of 
sulfoxidation as a regulatory switch. Methionine sulfoxide reductases catalyze the 
stereospecific reduction of methionine sulfoxide. One of the mammalian methionine 
sulfoxide reductases, MsrB3, has a signal sequence for entry into the endoplasmic 
reticulum (ER). In the ER, MsrB3 is expected to encounter a distinct redox environment 
compared to its paralogs in the cytosol, nucleus, and mitochondria.  
Aims: We sought to determine the location and arrangement of MsrB3 redox-active 
cysteines, which may couple MsrB3 activity to other redox events in the ER.  
Results: We determined the human MsrB3 structure using X-ray crystallography. The 
structure revealed that a disulfide bond near the protein amino terminus is distant in 
space from the active site. Nevertheless, biochemical assays showed that these amino-
terminal cysteines are oxidized by the MsrB3 active site after its reaction with methionine 
sulfoxide.  
Innovation: This study reveals a mechanism to shuttle oxidizing equivalents from the 
primary MsrB3 active site toward the enzyme surface, where they would be available for 
further dithiol-disulfide exchange reactions. 
Conclusion: Conformational changes must occur during the MsrB3 catalytic cycle to 
transfer oxidizing equivalents from the active site to the amino-terminal redox-active 
disulfide. The accessibility of this exposed disulfide may help couple MsrB3 activity to 
other dithiol/disulfide redox events in the secretory pathway.   
Keywords:  MsrB, disulfide, sulfenic acid, thiol-disulfide exchange, X-ray crystallography 
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Introduction 
The reversible modification of the sulfur-containing amino acid side chains cysteine and 
methionine is a common mechanism for regulation of protein function. Our knowledge of 
how cysteine side chains are oxidized and reduced is well advanced, but we are only 
beginning to appreciate how methionine side chains are reversibly modified (23). 
Methionine in proteins can be oxidized to methionine sulfoxide (MetSO) either non-
specifically by reactive oxygen species or as a specific, enzyme-catalyzed post-translational 
modification. Upon oxidation, the methionine sulfur atom becomes a new chiral center, 
producing methionine-R-sulfoxide or methionine-S-sulfoxide. Two main classes of 
Methionine sulfoxide reductase (Msr) enzymes catalyze the reverse process and restore 
the unmodified methionine: MsrA enzymes reduce the S epimer, and MsrB enzymes 
reduce the R epimer. As an example of regulation using this chemistry, enzymes of the 
Mical family stereoselectively oxidize methionine in actin, resulting in polymer disassembly 
(19), and cytosolic MsrB activity counteracts this process by reducing the actin methionine 
sulfoxides (28). MsrA is also involved in regulatory processes in the cell (33, 36). Though 
the catalytic activities of the two Msr classes are virtually identical, reactions on the 
epimers require a mirror-image positioning of functional groups in the enzyme active sites 
(32). MsrA and MsrB enzymes arose independently in evolution to act on the two forms of 
substrate (49).  
Eukaryotes, eubacteria, and archaea encode Msr enzymes (49). Structural and 
biochemical insights have largely come from the study of prokaryotic Msr versions (32, 41, 
44), but functional diversification of this enzyme family has occurred in multi-cellular 
organisms. Humans and other mammals have one MsrA and three MsrB paralogs, MsrB1, 
MsrB2, and MsrB3. MsrA is found in mitochondria and on the cytosolic face of endosomes 
(30). MsrB1 has an active-site selenocysteine and is found in the nucleus and cytosol (20). 
MsrB2 and MsrB3 both contain active-site cysteines, but MsrB2 is present in mitochondria, 
and MsrB3, the focus of this report, has distinct splice variants targeted to mitochondria 
(MsrB3B isoform) or the endoplasmic reticulum (ER) (MsrB3A isoform, hereafter referred 
to as MsrB3) (20, 21). Notably, MsrB3 genes exhibiting ER signal peptides and ER retention 
coding sequences are present in genomes spanning mammalian phylogeny (Fig. 1A). 
Experimentally fusing the MsrB3 signal peptide and ER retention signal onto MsrA 
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rerouted it to the ER, indicating that these sequences are functional for organelle targeting 
(24). Interestingly, an in-depth study of KDEL-like ER retention signals revealed that MsrB3 
remains localized to the ER even when truncated prior to its KAEL sequence (42). The 
mechanism for ER retention of MsrB3 is not fully resolved, but the signal sequence is 
clearly capable of ER targeting.  
Though the substrates of MsrB3 are as yet unknown, the enzyme has intriguing 
physiological associations. Human MsrB3 mutations are linked to non-syndromic deafness 
(5), and MsrB3 knockout correspondingly produces deafness in mice (47). MsrB3 
expression levels affect the resistance of stem cells to oncogene-induced DNA damage (34, 
39) and the resistance of cancer cells to apoptosis (26). MsrB3 expression were seen to 
change in patients with Alzheimer’s disease (4), and MsrB3 single nucleotide 
polymorphisms are associated with hippocampal volume (18). In plants, an ER-localized 
MsrB protects against oxidative stress upon exposure to cold (27). A key question is 
whether mammalian MsrB3 acts as a generic antioxidant enzyme or a specific regulatory 
factor in the ER, or both. Further study of adaptations of MsrB enzymes in mammals may 
provide insight into additional biochemical and functional capabilities.   
In addition to potential substrates and physiological pathways, another aspect of 
MsrB3 activity that is likely affected by subcellular localization is the reactivation step. The 
need for reactivation to complete a catalytic cycle arises from the MsrB mechanism: a 
round of MetSO reduction produces a selenocysteine selenenic acid or a cysteine sulfenic 
acid, which must be reduced to regenerate a functional enzyme active site. One common 
mechanism for reducing the active sites of MsrB enzymes is nucleophilic attack on the 
selenenic or sulfenic acid by the thiolate group of what is known as the “resolving” 
cysteine, forming a transient covalent link and liberating a water molecule. Reduction of 
the disulfide or selenium-sulfur bond, which can be accomplished by thioredoxin, then 
restores the active site (8). Despite the finding that aspects of normal ER function depend 
on the NADPH/thioredoxin reductase/thioredoxin system (38), thioredoxin itself is not 
present in the ER and therefore cannot directly reactivate MsrB3 in that compartment. 
Recycling of MsrB3 may involve glutathione or ER-localized thioredoxin-fold proteins, such 
as members of the protein disulfide isomerase (PDI) family, and MsrB3 may have unique 
characteristics enabling recycling in the ER environment. 
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According to amino acid sequence alignments, the positions of the resolving cysteines 
differ among the human MsrB paralogs (22). MsrB1 is predicted to have a resolving 
cysteine in the vicinity of the selenocysteine in the three-dimensional structure of the 
enzyme (22) (see also protein data bank (PDB) code 2MAO, in which the region of the 
resolving cysteine is absent), similar to the arrangement found in MsrB enzymes of many 
microorganisms (e.g., PDB code 3CXK). MsrB2 and MsrB3 lack a cysteine at the comparable 
position, but MsrB3 has two cysteines in a CX5C motif (in which X stands for a non-cysteine 
amino acid) closely following the signal peptide (Fig. 1A, B). Either of these CX5C cysteines 
can catalyze regeneration of the active site in enzyme assays when thioredoxin is supplied 
in vitro as the reductant (10). However, how these cysteines function together in the 
MsrB3 catalytic cycle in the ER is an open question. The amino terminal region of MsrB3 
shares no sequence homology with any MsrB enzyme with known structure nor with 
MsrA. To reveal the locations of the additional cysteines in the protein and, more 
generally, to provide the first structure of an Msr enzyme that functions in the ER, we 
determined the human MsrB3 structure using X-ray crystallography. Further biochemical 
analysis demonstrated that the redox state of the CX5C cysteines is coupled to activity at 
the enzyme active site.  
Results 
Structure determination and overall description 
Human MsrB3, lacking the signal peptide and carboxy-terminal KAEL sequence (Fig. 1), was 
produced in E. coli as a fusion with maltose binding protein (MBP). A tobacco etch virus 
(TEV) protease cleavage site enabled removal of the MBP. After cleavage and purification, 
MsrB3 was treated with dimethylamine-borane complex to methylate lysines as described 
(46), as attempts to crystallize the unmethylated protein were unsuccessful. The treated 
protein was crystallized using the hanging drop vapor diffusion method, and crystals 
diffracting to 1.87 Å resolution (Table I) were obtained. These crystals contained two 
MsrB3 molecules per asymmetric unit. The structure was solved by molecular replacement 
using a bacterial MsrB protein (PDB code 3CEZ) with high sequence identity to human 
MsrB3 (74 of 119 residues, or 62%) (6). Though the amino-terminal segment containing 
the CX5C cysteines did not exist in the search model, phase information from molecular 
replacement was sufficient to allow building of the remaining ordered regions. The MsrB3 
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structure could be built through residue 137 (numbered according to the mature protein 
sequence as in Fig. 1), but residues 138 to 156 were initially not visible in the electron 
density. A truncated version of MsrB3 was then produced, spanning residues 1 to 137 of 
the mature protein. This version was crystallized without reductive methylation in a 
different crystal form, also with two molecules in the asymmetric unit, and diffraction data 
were collected to 1.71 Å resolution (Table I). Molecular replacement using the initial 
MsrB3 model was used to phase the new crystal form. Upon further inspection of electron 
density maps from the full-length protein crystals, a segment corresponding to residues 
150 to 156, most likely arising from molecule B in the asymmetric unit, was detected 
making interactions with symmetry-related versions of both the A and the B molecules.    
As anticipated, the MsrB3 structure (Fig. 2A) has the characteristic Mss4-like fold (35, 
48) found for other MsrB proteins (32), consisting of two highly twisted, short-stranded β 
sheets. The active-site cysteine, Cys126, is displayed on the outer face of one of the sheets. 
The structural zinc binding site found in this fold family (48) is formed in MsrB3 from the 
four cysteine residues Cys54, Cys57, Cys103, and Cys106, positioned on two opposing 
loops. The cysteines Cys3 and Cys9, in the CX5C motif, were found disulfide bonded to one 
another adjacent to the zinc-coordinating site and far (~21 Å) from the active-site cysteine, 
Cys126. The four MsrB3 molecules from the two crystal forms are very similar, including in 
the CX5C region near the amino terminus, with Cα root mean square deviation (RMSD) 
values ranging from 0.5 to 1.0 Å for all pairwise comparisons (Fig. 2B). Certain structural 
features appear to stabilize the MsrB3 amino-terminal segment, including a cation-π 
interaction between the two helices that follow the CX5C region and the capping of the 
second helix by Arg4 in the CX5C loop (Fig. 2A). Nevertheless, the temperature factors of 
the first twenty residues are slightly higher than those of the underlying core fold (Fig. 2C). 
Notably, the CX5C cysteines are proposed to be the resolving cysteines that regenerate the 
MsrB3 active site after its oxidation to sulfenic acid (10) (Fig. 2D). To perform this function, 
the CX5C disulfide would first have to be reduced, and then either Cys3 or Cys9 would need 
to approach Cys126. Though the amino-terminal region is uniformly packed against the 
rest of the protein in the MsrB3 crystal structures, the CX5C disulfide is exposed to solution 
(Fig. 3A), and the disulfide is positioned in the correct geometry for an exogenous 
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reductant to perform nucleophilic attack along the Cys9-Cys3 sulfur-sulfur bond (13) (Fig. 
3B).  
Comparison with other MsrB structures 
Aside from the region of the CX5C cysteines, human MsrB3 shows a high degree of 
similarity to bacterial enzymes, represented in the protein structure data bank by 
Burkholderia pseudomallei methionine-R-sulfoxide reductase (PDB code 3CEZ; sequence 
identity 62% over 119 amino acids) (Fig. 4) and the MsrB domain of Neisseria gonorrhoeae 
PilB (PDB code 1L1D; sequence identity 49% over 135 amino acids). For 129 structurally 
aligned residues in each case, a Cα RMSD of only 0.8 Å was observed between human 
MsrB3 and each of these crystal structures according to an automated structure 
comparison against the protein data bank (17). In contrast, 3.3 Å and 3.2 Å RMSD values 
over only 83 and 94 residues, respectively, were measured in pairwise comparisons with 
the NMR structures of mammalian MsrB1 (PDB code 2KV1) (1) and MsrB2 (PDB code 2L1U) 
(2), despite 34% and 46% sequence identity in the aligned regions. The large differences 
measured between human MsrB3 and other mammalian MsrB enzymes may be due to 
insufficient restraints for NMR structure determination (2) and deviations from expected 
geometry in the NMR structure models, as identified using the Molprobity structure 
validation tool (11). Notably, the amino-terminal segments of the MsrB1 and MsrB2 
structures were particularly poorly resolved (1, 2), in contrast to the CX5C region of 
multiple MsrB3 molecules from the crystal structures, which showed homogeneous 
structure and packing (Fig. 2B).  
A feature shared between MsrB3 and certain homologous structures determined by X-
ray crystallography (e.g., PDB code 1L1D) is the presence of a solvent or buffer molecule in 
the active site, or covalent active-site modifications (Fig. 5). In the structure of the longer 
version of MsrB3, this species was modeled as 2-methyl-2,4-pentanediol (MPD) (Fig. 5A), 
which was present during crystallization and was consistent with the appearance of 
electron density in simulated annealing composite omit maps. Additionally, electron 
density corresponding to a sulfenic acid was seen for the active-site cysteine in this crystal 
form, with the hydroxyl group oriented toward a conserved pocket rich with hydrogen 
bond donors and acceptors (Fig. 5A). In particular, the side chain hydroxyls of Ser72 and 
Ser76, as well as a guanidinium nitrogen of Arg124, are all within about 3 Å of the hydroxyl 
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of the sulfenic acid. Though no substrate was added during the preparation of MsrB3 for 
crystallization, the sulfenic acid modification may have occurred as a byproduct of 
formaldehyde addition during the methylation reaction. The fortuitous modification of the 
active-site cysteine may help shed light on the mechanism for stabilizing the sulfenic acid 
intermediate and preventing it from engaging in unwanted reactions before it can be 
cleared by reduced resolving cysteines.  
Truncated MsrB3 also contained additional electron density in the active site (Fig. 5B). 
In this case, the species appeared to be covalently bound to the active-site cysteine. Based 
on previous observations that crystallization in the presence of cacodylate buffer can 
result in modified cysteine residues (31, 44), together with inspection of simulated 
annealing composite omit maps, the density was modeled as a dimethylarsinoyl 
modification, in which the arsenic is bonded to the cysteine sulfur by displacement of one 
of the oxygen atoms of the cacodylate. Ser72 and Ser76 coordinate a water molecule 
instead of a sulfenic acid in the dimethylarsinoyl-modified form. A comparison of the 
active-site regions of the two crystal forms shows good superposition of all the functional 
groups that are in hydrogen bonding distance of the sulfenic acid or bound water molecule 
(Fig. 5C). Only the region around Ser70, which forms hydrogen bonds to Ser72 and Ser76 
but is 4.0 Å away from the sulfenic acid, is altered in the dimethylarsinoyl-modified form 
due to a local and minor change in loop structure with a maximum backbone displacement 
of 2.7 Å (Fig. 5C).    
The MsrB3 resolving cysteines are oxidized by the active site 
Evidence to date indicates that Cys3 and Cys9 function as resolving cysteines in MsrB3 
(10). However, these cysteines are more than 21 Å away in Euclidean distance from the 
active-site Cys126 in the crystal structures presented here (Fig. 2A). Conformational 
changes have previously been observed in Msr enzymes to facilitate the engagement of 
the active-site cysteine by a resolving cysteine (40, 41). To examine biochemically whether 
the CX5C cysteines can function together to directly reduce the active site in the absence of 
another reductant, we reduced these cysteines with dithiothreitol (DTT), removed excess 
DTT, and supplied the reduced protein with MetSO to oxidize Cys126 to sulfenic acid. This 
and all subsequent experiments were done with the shorter version of MsrB3, ending at 
residue 137. After an incubation period, maleimide-functionalized polyethylene glycol 
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(PEG-mal) of molecular weight 5000 Da was added to modify remaining thiol groups. In 
this experiment, transfer of electrons from the reduced CX5C cysteines to the active site 
results in a CX5C disulfide, which does not react with PEG-mal. In addition, when the active 
site Cys126 is in sulfenic acid form it also becomes protected from PEG-mal modification. 
The number of PEG-mal modifications can be determined by the migration rate of the 
protein in gel electrophoresis, with cysteine mutants aiding in the assignment of PEG-
modified versions of the wild-type protein. For kinetic experiments of this type, electron 
transfer reactions can be quenched by rapidly lowering the pH, for example by adding 
trichloroacetic acid. The subsequent PEG-mal modification is carried out after removal of 
small-molecule oxidizing or reducing agents, when the protein is in the denatured state. 
This protocol is not suitable for MsrB3, however, as the four zinc-binding cysteines may 
react with PEG-mal if the zinc is removed by acidification and protein denaturation. 
Consequently, MsrB3 was treated with PEG-mal in the native state, and then DTT was 
added to react with remaining PEG-mal and to preserve the zinc-binding cysteines reduced 
and unmodified for gel electrophoresis.  
The first experiments to monitor electron transfer from the CX5C cysteines to the 
active site were conducted at a fixed incubation time. With increasing MetSO 
concentrations, MsrB3 became resistant to PEG-mal modification during the incubation, 
corresponding to protection of three cysteines (Cys3, Cys9, and Cys126) (Fig. 6A). The 
Cys3Ala/Cys9Ala mutant also became resistant to PEG-mal modification upon MetSO 
addition, due to sulfenic acid formation at Cys126. In contrast, the Cys126Ala mutant did 
not show any change in migration upon addition of MetSO, remaining sensitive to PEG-mal 
modification at Cys3 and Cys9 across the whole MetSO concentration range, indicating 
that oxidation of the CX5C cysteines depends critically on a functional active site. 
Comparing wild-type MsrB3 with the Cys3Ala/Cys9Ala mutant, it can be seen that 
protection of the mutant from PEG-mal modification occurred at lower MetSO 
concentrations (Fig. 6A). Low MetSO concentrations resulted in disappearance of fully 
reduced wild-type MsrB3, but a species with a single PEG-mal modification remained. This 
observation likely reflects the fact that the reduced wild-type protein can undergo two 
rounds of sulfenic acid formation at Cys126 when MetSO is added (Fig. 2D). The first 
sulfenic acid is restored to thiol form by the reduced CX5C cysteines, resulting in a CX5C 
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disulfide and PEG-mal reactivity at only Cys126. If the active site is oxidized a second time, 
there are no remaining CX5C thiols to reduce it, and the enzyme becomes protected from 
PEG-mal modification at all three redox-active cysteines.     
In principle, oxidation of the CX5C cysteines could occur intermolecularly. To test this 
possibility, the Cys3Ala/Cys9Ala and Cys126Ala mutants were mixed in the reaction, and 
the products were compared to those of each mutant alone. Under these circumstances, 
the Cys126Ala mutant became resistant to PEG-mal modification (Fig. 6B), indicating that 
intermolecular electron transfer from the resolving cysteines in one enzyme molecule to 
the active site of another enzyme molecule is a viable electron transfer route for MsrB3. 
However, comparing the kinetics of oxidation of wild-type MsrB3 with the kinetics of the 
mixture of the two complementary mutants demonstrated that the intramolecular 
electron transfer route is preferred when available (Fig. 6C). MetSO modification of the 
active site is rate-limiting for wild-type MsrB3, such that protection of the redox-active 
cysteines from PEG-mal modification was strongly dependent on MetSO concentration. In 
contrast, the mixture of cysteine mutants showed a weak dependence on MetSO 
concentration, suggesting that intermolecular electron transfer was rate limiting in this 
case. We conclude that intramolecular electron transfer efficiently regenerates a reduced 
MsrB3 active site and produces an oxidized CX5C motif, though intermolecular electron 
transfer occurs to some extent when the intramolecular route is unavailable. 
Analysis of a stabilized intermediate with a Cys9-Cys126 disulfide 
Reduction of the MsrB3 active site by the CX5C cysteines requires a disulfide intermediate 
between Cys3 or Cys9 and Cys126 (Fig. 2D). Nucleophilic attack on this intermediate by the 
partner CX5C cysteine would restore the Cys126 thiol and form a Cys3-Cys9 disulfide, 
suggesting that mutation of the attacking cysteine would stabilize the intermediate. We 
generated the Cys3Ala and Cys9Ala mutants and observed that both yielded a substantial 
fraction of oxidized monomeric species upon treatment with MetSO. The monomeric, 
oxidized Cys3Ala mutant (Fig. 7A) was purified from minor intermolecular disulfide 
contaminants by gel filtration. Monomeric, oxidized Cys3Ala was designated the “closed” 
form of this mutant because a putative intramolecular disulfide sealed off its active site. 
Despite obtaining high yields of homogenous closed Cys3Ala MsrB3 that could be 
concentrated to at least 20 mg/ml, numerous attempts to crystallize this variant, prepared 
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with or without reductive methylation, were unsuccessful. One explanation may be 
increased flexibility of the oxidized Cys3Ala, which was found to be much more sensitive 
than wild-type MsrB3 to proteolytic digestion using chymotrypsin (Fig. 7B). 
Optimized digestion of oxidized Cys3Ala using lower chymotrypsin concentrations 
revealed a preferred protease-sensitive site. Cleavage slowed the migration of the product 
in the oxidized state, a phenomenon likely due to an effect on the hydrodynamic 
properties of the protein rather than to an increase in size. In the reduced state, a major 
band that migrated more rapidly than the intact protein was detected, consistent with 
liberation of a disulfide bonded cleavage product (Fig. 7C). The intact and chymotrypsin-
clipped Cys3Ala were subjected to liquid chromatography mass spectrometry (LC-MS) (Fig. 
7D). Chymotrypsin cleavage produced a mass consistent with a species containing both 
termini of the protein but missing nine amino acids (residues 19 through 27) from the 
helical region downstream of the CX5C motif (Fig. 7E). Reduction of the cleaved protein 
produced the expected mass for the fragment spanning residue 28 to the carboxy 
terminus (Fig. 7D), indicating that the amino terminal region had indeed been linked to the 
carboxy terminal fragment by a disulfide bond. The chymotrypsin recognition sites, Leu18 
and Tyr27, are packed against one another and buried in the wild-type MsrB3 structure 
(Fig. 7E), but their protease sensitivity in the Cys3Ala intermediate-state mimic suggests 
that disulfide formation between Cys9 and Cys126 is facilitated by disruption of the helical 
region. Indeed, circular dichroism spectroscopy of oxidized Cys3Ala lacked the helical 
signal, a double minimum at 222 and 208 nm, exhibited by wild-type MsrB3 (Fig. 7F). The 
CX5C disulfide is not required to stabilize the MsrB3 helices, as the Cys3Ala/Cys9Ala mutant 
shows a helical signal similar to the wild-type enzyme (Fig. 7F). Considering the circular 
dichroism and chymotrypsin cleavage results together, the helical, amino-terminal region 
of oxidized Cys3Ala is structurally reorganized, but other parts of the MsrB3 protein 
appear to remain folded, as judged by the high selectivity of chymotrypsin cleavage 
despite the numerous possible protease recognition sites. 
Discussion 
The major finding from the human MsrB3 crystal structure is that the resolving cysteines, 
Cys3 and Cys9, form a disulfide bond and are distant from the active site in the observed 
conformation of the enzyme. This result could not readily have been predicted, as the 
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MsrB3 resolving cysteines are outside the region of homology with known structures of 
other MsrB proteins. In many bacterial MsrB enzymes, resolving cysteines are adjacent in 
space to the active-site cysteines within the core β-sheet-rich region of the fold (32). The 
mammalian MsrB proteins, however, have diverged from this paradigm and have a serine 
or threonine in place of the proximal resolving cysteine (22). Instead, the resolving 
cysteines of mammalian enzymes are located in different regions of their primary 
structures, and as the MsrB3 structure reveals, in different regions of the tertiary 
structure.  
Analyzing previous biochemical experiments in light of the MsrB3 structure now 
provides insight into the catalytic mechanism. In assays with purified enzyme, mutation of 
either Cys3 or Cys9 compromised regeneration of the MsrB3 active site by thioredoxin (10, 
22), while mutation of both cysteines together dramatically decreased recycling (10). 
These results demonstrate that thioredoxin does not directly reduce the sulfenic acid at 
the MsrB3 active site. Furthermore, the partial activity seen for the single mutants 
suggests that either of the CX5C cysteines can initiate mixed disulfide formation to expel 
the oxygen at the active-site cysteine sulfur. Nevertheless, the most effective version of 
the enzyme was wild-type MsrB3 containing both Cys3 and Cys9. The observation of a 
Cys3-Cys9 disulfide in the crystal structure suggests that, after a mixed disulfide has 
formed between one of the CX5C cysteines and the active-site cysteine, the other CX5C 
cysteine reduces the mixed disulfide, regenerating the active-site thiol and yielding the 
Cys3-Cys9 disulfide. Consistent with this notion is the observation that exposure of 
reduced MsrB3 to MetSO results in disulfide bond formation between Cys3 and Cys9 (Fig. 
6).  
The MsrB3 crystal structure further revealed that Cys9 is exposed to solvent and is 
thus the likely target for nucleophilic attack to reduce the Cys3-Cys9 disulfide and drive a 
further enzymatic cycle. The existence of a double-displacement mechanism, involving two 
successive thiol-disulfide rearrangements, has been described for E. coli MsrA (7), but in 
that case the two resolving cysteines are located near the carboxy terminus of the enzyme 
and are not disulfide bonded to one another in the structures that have been determined 
(44), thus differing from MsrB3.  
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While addressing certain mechanistic issues, the MsrB3 structure raises the questions 
how the distal cysteines interact with the MsrB3 active site and what evolutionary 
advantages arise from moving the resolving cysteines away from the active-site region 
(22). One possible answer is that the pair of resolving cysteines in MsrB3 may function in 
an analogous manner to the “shuttle” disulfides in other ER-localized enzymes that 
transfer electrons by dithiol-disulfide exchange. The direct electron donor for MsrB3 
recycling in its natural setting may be a member of the PDI family, as PDIs catalyze various 
thiol-mediated redox reactions in the ER such as formation of disulfides in secreted 
proteins, reduction of disulfides in proteins destined for degradation, and the reversible 
regulation of enzyme activity. In a number of cases, PDI-family oxidoreductases interact 
with shuttle disulfides instead of directly with core enzyme active sites. One example is 
Ero1, an ER sulfhydryl oxidase that generates disulfides by transferring electrons from 
cysteines to hydrogen peroxide (16). The Ero1 catalytic site consists of a disulfide in a CXXC 
motif adjacent to a bound flavin adenine dinucleotide cofactor (15). PDI family 
oxidoreductases do not directly access this active site, however, but rather reduce a CX4C 
disulfide (14) on an exposed flexible loop of Ero1 (15). The resulting reduced cysteines in 
the loop then reduce the Ero1 FAD-proximal disulfide, effectively shuttling electrons from 
PDI to the Ero1 active site. Another example of a shuttle disulfide in the ER occurs in the 
transmembrane protein VKOR (29). The VKOR CX7C shuttle disulfide transfers electrons 
from membrane-bound PDI family proteins to the VKOR active-site disulfide next to the 
quinone cofactor, from where they can be used to reduce vitamin K epoxide (43). It is 
thought that in general shuttle disulfides facilitate the function of redox enzymes by 
enabling substrate specificity to evolve independently of core catalytic activity (13), and 
MsrB3 may be another example of this phenomenon.   
Ero1, VKOR, and MsrB3 all appear to accept electrons from reduced cysteine thiolates 
via their shuttle disulfides. This mechanistic similarity suggests that one potential source of 
reducing equivalents for re-activating MsrB3 in the ER would be cysteines in nascent 
polypeptide chains, which might transfer electrons via PDI family proteins to MsrB3. Other 
sources of reducing equivalents in the ER are also possible, including reduced glutathione 
(25). For comparison, recycling of MsrB enzymes in the bacterial periplasm, an 
environment analogous to the ER in its support of oxidative protein folding, involves 
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electrons transferred across the cell membrane by the enzyme DsbD (9). It should be 
noted, however, that oxidized MsrB3 can convert free methionine to the sulfoxide (10), 
indicating that an environment that favors conversion of the MsrB3 active site to sulfenic 
acid will in turn drive formation of methionine sulfoxide. Whether the reaction runs in this 
direction in vivo in certain circumstances remains to be determined. 
Regardless of the direction of electron transfer, a key step in the MsrB3 mechanism 
requires the CX5C cysteines to approach the active-site cysteine, for which a major 
conformational change is required. The MsrB3 crystal structure shows that the amino-
terminal region containing the two helices is ordered and exhibits the same conformation 
in all four molecules in the two crystal asymmetric units in this study. The similarity 
between the organization of the two helices in MsrB3 and in the B. pseudomallei MsrB 
(Fig. 4) further suggests that this arrangement is not fortuitous but rather is a stable, 
evolved feature. Nevertheless, some movement of at least the amino-terminal of the two 
helices is likely required to enable the CX5C cysteines to reach the active site, as the 
segment of five amino acids between Cys9 and the start of the first helix is insufficient to 
span the required distance (Fig. 2A). Crystal structures of the X. campestris MsrB enzyme 
show how a polar pocket corresponding to the one that accommodates the sulfenic acid in 
MsrB3 is disrupted by a change in conformation to enable formation of a disulfide 
between the resolving and active-site cysteines in that enzyme (41). However, the 
resolving cysteine is downstream of the amino-terminal helices in X. campestris MsrB but 
upstream of the helices in animal MsrB3. Therefore, it is not yet clear whether the 
resolution of the active site in MsrB3 will similarly involve disruption of the polar pocket. In 
the current study, we detected changes in conformation and accessibility of the amino-
terminal region of the protein that likely facilitate approach of the resolving cysteines 
toward the enzyme active site. Now that the scale of the structural rearrangements 
required to resolve the sulfenic acid intermediate are known, how these rearrangements 
occur in MsrB3 and how ER factors engage the resolving cysteines to promote MsrB3 
recycling can begin to be investigated. 
Innovation 
The present study describes the first high-quality structures of a mammalian methionine 
sulfoxide reductase and reveals the spatial relationship between the resolving cysteines 
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and the catalytic center. Methionine sulfoxide reductase activity of human MrsB3, which is 
targeted to the endoplasmic reticulum, was shown to be coupled to the generation of a 
disulfide bond involving the resolving cysteines. The accessibility of this disulfide and its 
appropriate geometry for further dithiol-disulfide exchange reactions provides an 
explanation for how MsrB3 activity may be integrated into the redox environment of the 
secretory pathway. 
Materials and Methods 
Protein production and purification 
MsrB3 was produced as a fusion protein downstream of maltose binding protein, a His6 
tag, and a TEV protease cleavage site. Cleavage at the TEV site resulted in the following 
amino-terminal sequence: GEFQSGSC…, in which the underlined amino acids arise from an 
EcoR1 restriction site. Residue 1 in the MsrB3 structure corresponds to the first amino acid 
of the mature sequence according to UniProt (residue 33 of the MsrB3 precursor 
sequence) (45). The original expression construct extended through residue 156 of the 
mature protein, i.e., lacking only the KAEL sequence at the carboxy terminus. After the 
MsrB3 structure was solved using this construct, a second plasmid was generated by 
introduction of a stop codon after residue 137. Plasmids were transformed into the 
BL21(DE3) E. coli strain. Cultures were grown at 37 °C in the presence of 100 mg/L 
ampicillin to an optical density of 0.5 at 595 nm, at which point isopropyl β-D-1-
thiogalactopyranoside and zinc chloride were added, both at a concentration of 0.5 mM. 
The growth temperature was lowered to 25 °C, and the cultures were left to shake 
overnight. Cells were then pelleted, resuspended in 5 mM sodium phosphate, pH 7.5, 125 
mM NaCl, and 5 mM imidazole, and frozen at -80 °C. 
To purify the MsrB3 protein from bacterial cells, cell suspensions were thawed, and 
the protease inhibitors phenylmethylsulfonyl fluoride, leupeptin, and pepstatin were 
added. The cell suspensions were then sonicated on ice and spun at 25,000 g for 20 
minutes at 4 °C. Supernatant was applied to a Ni-NTA column, washed in the cell 
suspension buffer, and then eluted with an increasing imidazole gradient. Eluted protein 
was placed into a dialysis bag together with His6-tagged TEV protease and dialyzed against 
phosphate buffered saline (PBS) overnight at room temperature. The cleaved protein was 
reapplied to a Ni-NTA column, and MsrB3 was collected from the unbound, flow-through 
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fraction. The protein was exchanged using a PD-10 column (GE Healthcare #17-0851-01) 
into 25 mM HEPES buffer, pH 7.5, 250 mM NaCl, and the original, longer version was 
treated as described to methylate lysines (46). The methylated protein was then applied to 
a gel filtration column in the same buffer. The eluted protein was diluted to 10 mM HEPES, 
pH 7.5, 100 mM NaCl and concentrated to 15 mg/ml (~1 mM). The shorter MsrB3 protein 
was not methylated but was otherwise prepared in the same manner.    
Crystallization and structure solution 
The longer version of MsrB3 was crystallized by the hanging drop vapor diffusion method 
by mixing 1:1 protein stock with 1.6 M ammonium sulfate, 100 mM sodium cacodylate, pH 
7.4, and 200 mM sodium chloride at 20 °C. Crystals consistently grew as showers of small 
needles. In one instance, seeding from these crystals into a hanging drop 12 hours after 
mixing 1:1 with well solution containing the original crystallization solution plus 10% MPD 
produced larger, rod-shaped crystals. These crystals were used to collect the data enabling 
solution of the MsrB3 structure by molecular replacement. Molecular replacement was 
done using Phenix (3) with residues 10 to 139 of structure 3CEZ as the search model. 
Rebuilding was performed using Coot (12), and refinement was done using Phenix. The 
150-156 fragment was assigned to molecule B based on a gap of only 11 Å between 
residue 137 of molecule B and residue 150 of the fragment, but contiguous electron 
density linking residues 137 and 150 was not visible. 
The shorter version of MsrB3 crystallized in ~1.5 M ammonium sulfate, 100 mM 
sodium chloride, 50 mM cacodylate buffer, pH 6.8, and 15% glycerol. Phases were 
obtained by molecular replacement with a partially refined structure of MsrB3 obtained as 
described above.  
The quality of the MsrB3 structures was validated by Molprobity and by close 
inspection of composite simulated annealing omit maps calculated using Phenix. The 
models of the longer and shorter versions have no residues in disallowed regions of 
Ramachandran space. The longer form has 99.6% of residues in favored regions, whereas 
the truncated form has 98.9% of residues in favored regions. 
MetSO assays 
MsrB3 variants (short form) were reduced by incubating 200 µL of 100 µM enzyme with 20 
mM DTT for 30 min at room temperature. DTT was then removed by buffer exchange 
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using a PD-10 column equilibrated with PBS, collecting elution fractions of 0.5 mL. Protein 
concentrations were measured after elution, and reduced proteins were diluted to 10 µM 
in PBS. L-MetSO (Sigma #M1126) was dissolved at 100 mM in PBS, and dilution series were 
prepared. Reduced MsrB3 variants were mixed 1:1 with the L-MetSO dilutions and 
incubated for 15 min at 37 °C. During the incubation, 50 mg PEG-mal (5000 Da) (Iris 
Biotech GmbH #PEG1149) was dissolved in 200 µL water, yielding a solution of 
approximately 50 mM, and applied to a PD-10 column equilibrated in PBS to remove any 
unconjugated maleimide. Elution fractions of 0.5 mL were collected, and PEG-maleimide 
concentration was measured. To do so, a sample taken from the fraction that was faintly 
yellow in color was diluted 1:10 in PBS, and 20 µl of the dilution was mixed with DTT such 
that the final volume was 900 µl and the DTT concentration was 11.1 µM. After 5 min, 100 
microliters from a solution of 2 mM Ellman’s reagent (5,5’-dithiobis-(2-nitrobenzoic acid)) 
(TCI #D0944) dissolved in PBS was added, and the absorbance was measured. The 
decrease in absorbance was taken to indicate the concentration of DTT thiols alkylated by 
PEG-mal, and the concentration of the PEG-mal fraction from the PD-10 column was 
determined to be about 5 mM. A tenth of the reaction volume of PEG-mal was added to 
each MsrB3 sample at the end of the incubation with MetSO. After a further incubation for 
15 min at room temperature, DTT was added to a concentration of 50 mM. Five µL of each 
reaction was removed, 5 µL gel loading buffer was added, and the samples were loaded 
onto a 12% gel. To analyze the mixture of Cys3Ala/Cys9Ala and Cys126Ala, samples were 
prepared similarly except that proteins were diluted to 20 µM after removal of DTT using 
the PD-10 column, and 1:1:2 mixtures of protein:PBS:MetSO or protein:protein:MetSO 
were prepared for incubation at 37 °C.  
For kinetic experiments, reactions were performed at 37 °C in a volume of 8 µL and 
initiated by addition of MetSO. At the indicated time points, samples were removed from 
37 °C, and a tenth of the reaction volume of PEG-mal was added at room temperature. It 
should be noted that PEG-mal reacts rapidly but not instantaneously with MsrB3 cysteines, 
such that the early timepoints reflect a competition between PEG-mal alkylation of all 
remaining cysteine thiols and MetSO sulfenylation of the active site. Half an hour after the 
final PEG-mal addition of the time-course, 1 µL of 1 M DTT and 5 µL gel loading buffer were 
added to each tube. Samples were applied to a 12% polyacrylamide gel.   
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Limited proteolysis 
The shorter version of wild-type MsrB3 and the oxidized Cys3Ala variant were incubated at 
37 °C for 1 hr at a concentration of 45 µM in PBS with various concentrations of TLCK-
treated chymotrypsin (Chem-Impex International, Inc. #01783). The highest chymotrypsin 
concentration was 100 µg/mL for Fig. 7B and 10 µg/mL for Fig. 7C, and successive lanes 
represent two-fold dilutions of protease. Cleavage was stopped by the addition of 
phenylmethylsulfonyl fluoride. Gel loading buffer containing either 20 mM N-ethyl 
maleimide or 20 mM DTT was then added, and samples were applied to 15% 
polyacrylamide gels. 
Mass spectrometry 
Uncleaved or chymotrypsin-cleaved Cys3Ala was applied to LC-MS with or without prior 
reduction using DTT. LC-MS runs were performed on a Waters AC        C class   
instrument, in positive ion mode using electrospray ionization.    C separation used a C4 
column (300  ,  .  μm, 2  mm ×  00 mm).  he column was held at 40 °C and the 
autosampler at 10 °C. Mobile solution A was 0.1% formic acid in water, and mobile phase B 
was 0.1% formic acid in acetonitrile. The run flow was 0.4 mL/min with gradient 20% B for 
2 min, increasing linearly to 60% B for 3 min, holding at 60% B for 1.5 min, changing to 0% 
B in 0.1 min, and holding at 0% for 1.4 min. Mass data were collected in the range of 700 
to 1550 m/z on a Waters SQD2 detector. Deconvolution was performed using the 
MassLynx program with MaxEnt processing in the range of 9,000-20,000 Da. Calculations 
of expected masses were based on monoisotopic mass and included oxidation of the single 
methionine in the sequence. The loss of two protons for a disulfide bond in the oxidized 
samples was taken into account. 
Circular dichroism spectroscopy 
Proteins were diluted 100-fold from 1 mM stocks (prepared as for crystallization) into 10 
mM sodium phosphate buffer, pH 7.4. Data were collected at 24 °C on a Chirascan circular 
dichroism spectrophotometer (Applied Photophysics) in automated signal acquisition 
mode and presented as an average of five repeats. 
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Abbreviations used 
DTT = dithiothreitol 
ER = endoplasmic reticulum 
MBP = maltose binding protein 
MetSO = methionine sulfoxide 
MPD = 2-methyl-2,4-pentanediol (MPD) 
Msr = methionine sulfoxide reductase 
PBS = phosphate buffered saline 
PDB = protein data bank 
PDI = protein disulfide isomerase 
PEG-mal = maleimide-functionalized polyethylene glycol 
RMSD = root mean square deviation 
TEV = tobacco etch virus 
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Table 1. Data collection and refinement statistics. 
Data collection Msrb3 (1-156) Msrb3 (1-137) 
Space group P212121 P21212 
Unit cell dimensions   
     a, b, c (Å) 44.05, 65.30, 112.89 81.15, 85.71, 49.17 
     α, β, γ (°) 90, 90, 90 90, 90, 90 
Resolution (Å) 1.85 1.71 
Rpim 0.105 0.041 
Mean I/σ(I) 4.9 11.3 
Completeness (%) 99.8 99.2 
Multiplicity 6.7 4.2 
Wilson B factor (Å2) 16.4 22.15 
   
Refinement   
Resolution (Å) 42.67 – 1.87 42.65 – 1.71 
No. reflections/test set 27,651/1383 37,458/1835 
Rwork/Rfree 0.182/0.226 0.174/0.222 
No. atoms1    
     Protein  2223 2194 
     Water 325 352 
     Other 43 16 
RMSD from ideal geometry   
     Bond lengths (Å) 0.007 0.007 
     Bond angles (°) 0.899 0.835 
Ramachandran favored (%) 99.60 98.90 
Ramachandran outliers (%) 0 0 
Rotamer outliers 0 0.82 
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1 Covalent modifications of protein amino acids, including methyl groups on lysine and the 
dimethylarsinoyl modification of cysteine, are included in “other.” Also included in “other” 
are MPD and zinc, sulfate, and chloride ions. Only non-hydrogen atoms were counted. 
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Figure legends 
 
FIG. 1. MsrB3 sequence. (A) Amino acid sequence alignments of the amino- and carboxy 
termini of representative mammalian MsrB3 orthologs (Homo sapiens, Oryctolagus 
cuniculus, Erinaceus europaeus, Felis catus, Bos taurus, Globicephala melas, Ceratothenium 
simum, Pteropus vampyrus, Ailuropoda melanoleuca, and Vombatus ursinus). Predicted 
signal sequences for ER targeting are highlighted in violet. Dashes indicate gaps in the 
alignment; dots indicate intervening sequence that is not shown. The CX5C motif, including 
the identities of the residues between the two cysteines, is highly conserved. KDEL-like ER 
retention signals are present at the carboxy termini. (B) Sequence of the precursor of ER-
localized human MsrB3 with secondary structure annotations according to the structure 
reported herein. The signal peptide is highlighted in violet/pink, with two arrows indicating 
possible cleavage sites generating the mature protein. The first arrow indicates the site 
predicted using SignalP (37). The second site and resulting numbering of the mature 
sequence are according to UniProt (45). The KDEL-like ER retention signal (KAEL in human 
MsrB3) is highlighted in light blue. Cysteine amino acids are highlighted in yellow. The blue 
oval represents a zinc ion coordinated by cysteine residues. The active-site cysteine is 
indicated by an orange star, and the putative resolving cysteines by an overline labeled 
CX5C. Cylinders indicate helices; arrows indicate β-strands. The dashed segment indicates a 
region for which no electron density was evident in the crystallographic maps. 
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FIG. 2. Structure of human MsrB3. (A) Ribbon diagram of MsrB3 with cysteine side chains 
shown as spheres with van der Waals radii. Residues 1 to 32 are displayed in a rainbow 
gradient (red → blue).  he termini are labeled in gray, with the red “N” and arrowhead 
indicating the first amino acid in mature MsrB3. The dashed black line indicates the 
distance between the putative resolving cysteines and the active site. The series of yellow 
dots indicates a C-capping interaction between Arg4 and the carboxy terminus of the blue 
helix. (B) Superposition of the four molecules in the asymmetric units of the MsrB3 crystals 
(truncated version chain A blueand chain B green; full-length version chain A magenta and 
chain B cyan). The zinc ion is shown as a cyan sphere, and cysteines are in stick 
representation. (C) MsrB3 (chain B of the truncated form) colored according to Cα 
temperature factors (blue low, orange high). Cysteines are in stick representation. (D) 
Schematic of the MsrB3 reaction cycle (10). The bracketed species are two alternatives for 
this step in the cycle.  
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FIG. 3. Accessibility of the CX5C disulfide loop. (A) Surface representation of MsrB3 
showing solvent exposure of the active-site cysteine (Cys126) and Cys9 of the Cys3-Cys9 
disulfide. (B) In a semi-transparent sphere representation, it is evident that Cys9 in the 
Cys9-Cys3 disulfide (sticks) is accessible for nucleophilic attack in the preferred geometry, 
along the axis of the sulfur-sulfur bond (13), as indicated by the red arrow in the upper 
panel. The lower panel is oriented such that the nucleophile would approach from above 
the plane of the page.  
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FIG. 4. Comparison of human MsrB3 with a bacterial MsrB homolog. A superposition of 
human MsrB3 (magenta) and B. pseudomallei MsrB (blue; PDB code 3CEZ) is shown in two 
views. The human and bacterial structures show remarkable similarity, with an RMSD of 
only 0.8 Å for Cα atoms and precise structural alignment of the zinc-binding region (cyan 
sphere in left view) and the active-site cysteines (indicated by the C126 label in the view on 
the right). No segment corresponding to the Cys3-Cys9 disulfide of MsrB3, however, is 
present in the bacterial enzyme, and human MsrB3 lacks a cysteine at the position of the 
resolving cysteine in B. pseudomallei.  
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FIG. 5. MsrB3 active-site region in the two crystal forms. (A) MsrB3 bearing a sulfenic acid 
in the active site. Hydrogen bonds involving the sulfenic acid are shown by dashed lines. 
(B) Dimethylarsinoyl ((CH3)2AsO) cysteine derivative of MsrB3. Hydrogen bonds to the 
bound water molecule are indicated. (C) Superposition of long (carbon atoms colored 
white) and short (carbon atoms colored peach) versions of MsrB3 corresponding to the 
forms shown in panels A and B, respectively. The different positions of Ser70 in the two 
structures may be a result of crystal packing and a nearby bound sulfate in the structure of 
truncated MsrB3. 
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FIG. 6. Addition of MetSO results in oxidation of the CX5C cysteines mediated by the 
active site. (A) The indicated MsrB3 variants were supplied to a set of parallel reactions 
with the CX5C and active-site cysteines (when present) reduced. MetSO was added from a 
series of two-fold dilutions. Some of the MetSO concentrations in the reaction are labeled 
on the wedge above the gels.  After a 15 minute incubation, PEG-mal was added to modify 
remaining free thiols. Resistance to PEG-mal modification at increasing MetSO 
concentrations was a result of disulfide formation by the CX5C cysteines and sulfenic acid 
formation at the active site. The Cys126Ala active-site mutant showed no change with 
MetSO addition, indicating that Cys126 normally catalyzes oxidation of the Cys3-Cys9 
disulfide in the presence of MetSO. (B) Electron transfer between the resolving cysteines 
and the active site can occur intermolecularly. Cys126Ala is not oxidized in 15 minutes 
when treated with MetSO, but it becomes oxidized and resistant to PEG-mal modification 
when Cys3Ala/Cys9Ala, which contains a functional active site, is also present. MetSO was 
supplied as a series of four-fold dilutions. (C) A kinetic analysis showed that protection of 
Cys3 and Cys9 from PEG-mal modification in the Cys126A mutant by mixing with the 
Cys3A/Cys9A mutant occurred slowly at two MetSO concentrations. In contrast, disulfide 
formation and protection from modification occurred rapidly in the wild-type enzyme at 
the higher MetSO concentration. At the higher concentration, MetSO competed with PEG-
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mal for the active site, such that the zero and early time points show some degree of 
protection of Cys126 from PEG-mal. Together these experiments show that oxidation of 
the CX5C cysteines is more efficient by intra- than intermolecular electron transfer and that 
intramolecular transfer is limited by the rate of active-site modification in the range of 
MetSO concentrations studied.  
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FIG. 7. Internal disulfide bond and increased protease sensitivity in the Cys3Ala 
intermediate-state mimic. (A) Treatment of the Cys3Ala mutant with MetSO produced a 
species that is non-reactive with PEG-mal. Shown for comparison are untreated wild-type 
MsrB3 and the Cys3Ala/Cys9Ala mutants, which receive one PEG-mal modification at 
Cys126. The Cys126Ala mutant is resistant to modification because the remaining redox-
active cysteines are protected in a Cys3-Cys9 disulfide. (B) MetSO-treated Cys3Ala is more 
sensitive than wild-type MsrB3 to proteolysis with chymotrypsin. Wedges represent a 
range of chymotrypsin concentrations. Samples from the digestions were applied to gels in 
the oxidized (ox) form or after reduction (red) with DTT. (C) Limit proteolysis produced a 
species that migrated more slowly than the uncleaved protein under oxidizing (C3A ox) 
conditions. Under reducing conditions (C3A red), a fragment that migrated faster than the 
full-length protein was liberated. A sample prepared as for the lanes indicated by red 
arrowheads was applied to LC-MS. (D) LC-MS results for the species indicated in panel C 
and for uncleaved controls. Measured masses are shown for the major peak in each 
sample. In parentheses are the calculated masses for each species, amino acid sequences 
of which are shown below the spectra. Amino acids remaining from the cloning site and 
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TEV cleavage of the fusion protein, and that are not part of MsrB3, are underlined. The 
“cleaved” sample was assigned as a species missing residues  9-27 but containing amino-
terminal residues linked by a disulfide to the carboxy-terminal region.  he “cleaved + D  ” 
sample was assigned as residues 28 to 137, the latter being the carboxy terminus of the 
short MsrB3 variant. (E) The chymotrypsin-sensitive segment of oxidized Cys3Ala is shown 
in the context of the structure of wild-type MsrB3, in which this segment is folded and 
protected. The conformation of oxidized Cys3Ala is expected to be different from the 
structure shown because it contains a disulfide between Cys9 and Cys126. Furthermore, 
proteolytic cleavage of the Cys3Ala intermediate-state mimic occurred at the peptide 
bonds following Leu18 and Tyr27, which are not exposed in the wild-type structure. (F) 
Circular dichroism spectra of wild-type MsrB3, the Cys3Ala/Cys9Ala mutant, and the 
oxidized Cys3Ala intermediate-state mimic. Oxidized Cys3Ala shows loss of helical signal 
(minima at 222 and 208 nm). 
